Canaccord Genuity Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $85

Benzinga Newsdesk www.benzinga.com Neutral 56.8%

Neg 0% Neu 56.8% Pos 0%

Canaccord Genuity analyst Gary Nachman maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lowers the price target from $95 to $85.